Friday, 15 Dec 2017

You are here

ACR17 Good News – Ankylosing Spondylitis and Spondyloarthritis

The following is a collection of AS/SpA-specific mentions culled from RheumNow's coverage of the Annual ACR 2017 meeting in San Diego.

Visit our RheumNow annual meeting site to read our gout content -

Specific items:

  • Bone marrow oedema in sacroiliac joints is common (30-40%) in young athletes and is most frequent in the posterior lower ilium.  Weber et al
  • Only 9-14% people with chronic backache see a rheumatologist 
  • Increased risk of CVA, but not for MI, in AS pts. Abstract #2972
  • Low mean change in radiographic change after 4 years of Secukinumab treatment in AS, Braun 
  • Smoking is associated with higher disease activity and worse quality of life in SpA patients. Abstract #2506
  • IBD is assoc.tih more severe SpA. Occurs w/ rate of 0.7/100 patient-yrs/ 5 yrs in DESIR cohort. Abstract #2512
  • FUTURE5: Cosentyx clinically &radiographically superior to PBO. mTSS non-progression rate = 88% for Cosentyx vs 73% PBO #L17 #acr17
  • Dheodar et al-Large study on impact of TNFi on xtra art. comorbidities in AS. Abstract #1527
  • Don't discount spondyloarthropathy in pts >45yo, especially if pt has psoriasis or inflammatory back pain. Abstract #2037
  • Low DMARD use on AS pts on chronic opioids Abstract #1548
  • Significant reduction in immunosuppression load on uveitis pts with long term ADA use. Abstract #1115
  • Abstract #1881  Uveitis & scleritis common in AI disease. Lack of consensus on workup guidelines; calls for Ophth/Rheum collaboration
  • Gut-derived TNF: Connection Between Crohn’s and SpA and Sacroiliitis
  • Landewe Plenary session: Stopping adalimumab in nrAxSpA patients in sustained remission leads to flare after 8-12 weeks in 53%
  • Plenary Abstract #1787 Landawe presents Atlas 5 study, continuation of ADA is assoc with significantly less flares in nr-AxSpA
  • uSpA pts are younger, more likely +HLA-B27, and higher CRP than nrSpA pts. Abstract  #1506
  • Chronic reactive arthritis due to chlamydia could be treated with longterm antibiotics with up to 70% achieving remission
  • Reactive Arthritis 
  •  The Red Eye in the Rheumatology Patient
  • Higher risk of VTE on patients hospitalized with SpA, comparable with that of malignancy>OA Abstract #879
  • There was 12% progression in 2yrs to AS from nrAxSpA
  • 53% risk of VTE and 62% DVT in AS compared to general population. Confounders not measured Abstract #3S078
  • Higher prevalence of venous thrombosis in SpA admissions- Inflammation driven thrombosis & NSAIDs to blame? Dilli Poudel Abstract #879
  • Higher risk of VTE on patients hospitalized with SpA, comparable with that of malignancy, but > than OA Abstract #879
  • Abstract #578 Of 10 Biomarkers, combo of 2 showed small value added in terms of rad.progression in AxSpA
  • Abstract #593  EarlyAxSpA DESIR 5 year data showed low rates of structural progression-SI fatty lesions
  • Dr L Gensler at #ACR17: says tobacco use decreases efficacy of TNF inhibitors
  • Dr L Gensler: UK database 1 out of 4 pts with ank spond will have had uveitis after 20 years of AS
  • Dr L Gensler: EDS and JHS can mimic inflammatory arthritis and spondyloarthritis
  • Dr L Gensler: X-rays unreliable to detect sacroilitis; limited CT is gold std. MRI is better
  • In the evaluation of axial spondyloarthropathies MRI without Gad and CRP over ESR are preferred. (LianneGensler)
  • DDX of sacroiliitis: Osteitis condensans ilii -CRP normal, multiparous women with back pain, even with subtle bone marrow edema.

AS/SpA Videos

Dr. Julio Gonzalez: Psoriatic Arthritis and Axial Spondyloarthropathy Studies


Dr. Rachel Tate: Gender Bias in AS 


Dr. Rachel Tate: Adalimumab and Disease Remission in non-Radiographic Axial SpA



Dr. David Borenstein: Back Pain

The author has received research/grant financial support on this subject
The author has received compensation as an advisor or consultant on this subject

Add new comment

More Like This

FDA Approves Xeljanz for Use in Psoriatic Arthritis

Pfizer Inc. announced today that the United States Food and Drug Administration (FDA) has approved Xeljanz (tofacitinibi) for the treatment of adult patients with active psoriatic arthritis (PsA) who have had an inadequate response or intolerance to methotrexate or other disease-modifying antirheumatic drugs (DMARDs).

2017 Update of Treat to Target Recommendations for SpA/PsA

A 2017 international committee of experts met to assess and revise its earlier 2012 recommendations regarding treating to target in patients with psoriatic arthritis (PsA) and axial peripheral spondyloarthritis (SpA). 

Ixekizumab (Taltz) FDA Approved for Psoriatic Arthritis

On Friday, December 1st, the FDA approved Lilly's drug Taltz (ixekizumab) for use in adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. 

Taltz, an IL-17 inhibitor, has previously been approved for plaque psoriasis where it has shown high level PASI75 and PASI100 responses.

MTX Doubles Hepatotoxicity Risk in Psoriasis Patients

A study from the University of Pennsylvania Perelman School of Medicine was published in the Journal of Investigative Dermatology showing that the risk of incident liver disease doubled when patients with psoriasis (PsO) or psoriatic arthritis (PsA) take methotrexate (MTX), but not when MTX is used in rheumatoid arthritis. (Citation source

Several Agents Score on Radiographic Progression in Psoriatic Arthritis

Reduction on radiographic progression has now become the standard of care in the therapies used to treat psoriatic arthritis and, during the 2017 ACR Meeting, several agents reported the results of their studies with radiographic endpoints.